Title: One-carbon metabolism-related compounds are associated with epigenetic aging biomarkers: Results from National Health and Nutrition Examination Survey (NHANES) 1999-2002

Authors: Anne Bozack,¹ Dennis Khodasevich,¹ Jamaji C. Nwanaji-Enwerem,² Nicole Gladish,¹ Hanyang Shen,¹ Saher Daredia,³ Mary Gamble,⁴ Belinda L. Needham,⁵ David H. Rehkopf,^{1,6,7,8,9} Andres Cardenas^{1,8}

Affiliations: 1. Department of Epidemiology and Population Health, Stanford University, Palo Alto, CA, US

2. Department of Emergency Medicine, Center for Health Justice, and Center of Excellence in Environmental Toxicology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, US

3. Department of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, CA, US

4. Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, NY, US

- 5. Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, US
- 6. Department of Health Policy, Stanford University, Palo Alto, CA, USA

7. Department of Medicine - Primary Care and Population Health, Stanford University, Palo Alto, CA, US

8. Department of Pediatrics, Stanford University, Palo Alto, CA, USA

9. Department of Sociology, Stanford University, Palo Alto, CA, USA

Sources of support: AKB is supported by the National Institutes of Health (NIH) grant K99ES035109. JNE and AC are supported by the NIH grant R01ES031259. This research was also supported by the National Institute on Minority Health and Health Disparities (R01MD011721, MPI: BLN and DHR; and R01MD016595). The funders had no role in the decision to publish, preparation, review, or approval of the manuscript.

Corresponding author: Anne K. Bozack; 1701 Page Mill Rd., Palo Alto, CA, 94304; abozack@stanford.edu

Abbreviations: ADM: adrenomedullin; B2M: β -2 microglobulin; BKMR: Bayesian Kernel Machine Regression; BMI: body mass index; BMIO: beta mixture quantile; CI: confidence interval; CpG: cytosine-guanine dinucleotide; CRP: C-reactive protein; CVD: cardiovascular disease; DNAmTL: DNA methylation telomere length; DunedinPoAm: Dunedin Pace-of-Aging; EAD: epigenetic age deviation; Hcv: homocysteine; HHS: Department of Health and Human Services; GDF-15: growth differentiation factor 15; MAE: median absolute error; MMA: methylmalonic acid; NCHS: National Center for Health Statistics; NHANES: National Health and Nutrition Examination Survey; OCM: one-carbon metabolism; PAI-1: plasminogen activation inhibitor 1; PIR: poverty to family income ratio; QC: quality control; RBC: red blood cell; SAH: S-adenosylhomocysteine; SAM: S-adenosylmethionine; SD: standard deviation; TIMP-1: tissue inhibitor metalloproteinase 1; US: United States

1 Abstract

2	Background: One-carbon metabolism (OCM), a biochemical pathway dependent on
3	micronutrients including folate and vitamin B12, plays an essential role in aging-related physiological
4	processes. DNA methylation-based aging biomarkers may be influenced by OCM.
5	Objective: This study investigated associations of OCM-related biomarkers with epigenetic aging
6	biomarkers in the National Health and Nutrition Examination Survey (NHANES).
7	<i>Methods:</i> Blood DNA methylation was measured in adults aged \geq 50 years in the 1999-2000 and
8	2001-2002 cycles of NHANES. The following epigenetic aging biomarkers were included: Horvath1,
9	Horvath2, Hannum, PhenoAge, GrimAge2, DunedinPoAm, and DNA methylation telomere length
10	(DNAmTL). We tested for associations of serum folate, red blood cell (RBC) folate, vitamin B12,
11	homocysteine, and methylmalonic acid concentrations with epigenetic age deviation (EAD) among 2,346
12	participants with epigenetic and nutritional status biomarkers using survey weighted general linear
13	regression models adjusting for sociodemographics, BMI, and behavioral factors.
14	Results: A doubling of serum folate concentration was associated with -0.82 years (95%
15	confidence interval (CI) = -1.40, -0.23) lower GrimAge EAD, -0.13 SDs (-0.22, -0.03) lower
16	DunedinPoAm, and 0.02 kb (0.00, 0.04) greater DNAmTL EAD. Associations were attenuated after
17	adjusting for smoking status and alcohol intake, folate antagonists. Conversely, a doubling in
18	homocysteine concentration was associated with 1.05 years (0.06, 2.04) greater PhenoAge EAD, 1.93
19	years (1.16, 2.71) greater GrimAge2 EAD, and 0.26 SDs (0.10, 0.41) greater DunedinPoAm.
20	Associations with GrimAge2 EAD and DunedinPoAm were robust to alcohol and smoking adjustment.
21	Conclusions: In a nationally representative sample of U.S. adults, greater folate, a carbon donor,
22	was associated with lower EAD, and greater homocysteine, an indicator of OCM deficiencies, was
23	associated with greater EAD; however, some associations were influenced by smoking status. Future
24	research should focus on high-risk populations. Randomized controlled trials with long-term follow-up
25	are also needed to established causality and investigate the clinical relevance of changes in EAD.
26	

- 27 Keywords: one-carbon metabolism, epigenetic aging, DNA methylation, folate, homocysteine, vitamin
- 28 B12, National Health and Nutrition Examination Survey (NHANES)

29 Background

30	One-carbon metabolism (OCM) is a biochemical pathway essential for supporting many
31	physiological processes. OCM produces the universal methyl donor S-adenosylmethionine (SAM), a
32	cofactor for methylation of DNA, proteins, amino acids, and other small molecules. OCM also includes
33	the transsulfuration pathway, which generates the antioxidant glutathione, and provides one-carbon units
34	for purine and thymidylate biosynthesis. OCM plays an essential role in aging-related processes by
35	supplying methyl groups, producing building blocks for DNA synthesis and repair, and maintaining redox
36	balance in cells. ¹ Deficiencies or imbalances in OCM increase the risk of aging-related physiological
37	changes and diseases ¹⁻³ and may influence aging-related biomarkers.
38	OCM is dependent on diet-derived micronutrients including folate (vitamin B9) and cobalamin
39	(vitamin B12) ⁴ (Figure 1 ; adapted from ⁵). Naturally occurring folates are found in foods such as
40	vegetables, fruits, legumes, and nuts. Folic acid is a synthetic, stable form of folate used in supplements
41	and fortified foods. Folate facilitates the recruitment of methyl groups to OCM, which are subsequently
42	used to remethylate homocysteine (Hcy) to methionine, the precursor of SAM, by methionine synthase
43	using B12 as a cofactor. Upon donation of a methyl group, SAM is converted to S-adenosylhomocysteine
44	(SAH), a product inhibitor of most methylation reactions, which can be hydrolyzed to Hcy and
45	remethylated to methionine given adequate folate and B12. B12 is also involved in the metabolism of
46	methylmalonic acid (MMA), a byproduct of propionate metabolism. ⁶ High Hcy concentration is an
47	indicator of folate or B12 deficiency, and high MMA concentration is an indicator of B12 deficiency. ^{7,8}
48	The prevalence of folate and B12 deficiencies increases with age due to changes in diet, intestinal
49	absorption, and use of antagonistic therapeutic drugs. ^{9,10} Low folate levels, which can have mutagenic
50	effects due to reduced thymidylate biosynthesis and increased uracil misincorporation, ¹¹ have been
51	associated with age-related conditions, including dementia, ¹² cognitive function, ¹³ and cancers. ^{14,15} Folate
52	and B12 deficiencies also contribute to disease risk by increasing Hcy concentration. Hcy can induce
53	oxidative stress, inflammation, and impaired endothelial function. ¹⁶ Elevated Hcy has been associated
54	with increased risk of cardiovascular disease (CVD) incidence and mortality, ¹⁷ cognitive impairment and

decline.¹⁸ particularly in groups with existing neurological disorders,^{19–21} and all-cause mortality,¹⁷ 55 although associations may vary by population due to differences in diet, age, and genetic factors.²² 56 57 In recent years, the study of aging and the healthspan has advanced with the development of 58 epigenetic aging biomarkers, also known as epigenetic clocks. These biomarkers leverage DNA 59 methylation levels at specific cytosine-guanine dinucleotides (CpG sites) that change with age. This 60 phenomenon has been leveraged to train epigenetic clocks as linear combinations of DNA methylation 61 levels at age-related CpGs. Epigenetic clocks can be broadly classified as predictors of chronological age (*i.e.*, first-generation clocks),^{23,24} aging-related phenotypes and mortality risk (*i.e.*, second-generation 62 clocks).^{25–27} and rate-of-aging (*i.e.*, third generation clocks).²⁸ Epigenetic age deviation (EAD), or the 63 64 difference between epigenetic and chronological age, is strongly associated with cognitive impairment, dementia, BMI, cancer, CVD, other morbidities, and all-cause mortality.^{29,30} Second generation clocks 65 have proven to be particularly strong predictors of cancer, CVD, comorbidity, and time to death^{25,27} — 66 67 aging-related outcomes that may have etiologies related to OCM deficiencies. 68 Testing the relationship between markers of OCM and EAD can advance our understanding of 69 how nutritional factors and OCM function are related to complex aging- and disease-related processes and 70 can inform the application of epigenic aging biomarkers in research and clinical settings. In this study, we 71 aimed to investigate associations of OCM-related micronutrients and biomarkers with EAD among 72 participants in the National Health and Nutrition Examination Survey (NHANES), a nationally 73 representative sample of adults in the United States (US). Our study focused on concentrations of the B vitamins folate and B12, Hcy, and MMA and seven epigenetic aging biomarkers (Horvath1,²³ Horvath2,²⁴ 74 Hannum.³¹ PhenoAge.²⁵ GrimAge2.²⁶ DunedinPoAm.²⁸ and DNA methylation telomere length 75 (DNAmTL)³²). We hypothesized that promoters of OCM (*i.e.*, folate and B12) would be associated with 76 77 lower EAD, whereas indicators of OCM deficiencies (*i.e.*, Hcy and MMA) would be associated with 78 increased EAD.

79

80 Methods

81 Study population

82	We leveraged data from the 1999-2000 and 2001-2002 cycles of NHANES. NHANES is an
83	ongoing program conducted by the National Center for Health Statistics (NCHS) that includes interviews,
84	physical exams, and laboratory measurements and is designed to evaluate and monitor the health and
85	nutrition among noninstitutionalized adults and children in the US. ³³ In the 1999-2000 and 2001-2002
86	cycles of NHANES, DNA methylation was measured in blood samples of a subset of adults aged 50 years
87	or older. To protect participant confidentiality, participants ≥ 85 years were top coded as 85 years old.
88	Consequently, all participants assigned an age of 85 years were excluded from our analyses as we were
89	unable to determine their true chronological age. Our study included 2,346 adults with available DNA
90	methylation data and nutritional biomarkers after excluding sex-mismatches and participants 85 years and
91	older (Supplemental Figure 1). All participants provided written informed consent, and the study
92	protocols were approved by the NCHS Research Ethics Review Board. ³⁴
93	DNA methylation
94	A detailed description of DNA methylation laboratory methods and data processing can be found
95	on the NHANES website. ³⁵ In the 1999-2000 and 2001-2002 cycles of NHANES, DNA methylation was
96	measured in blood samples of 2,532 adults. Samples were selected for DNA methylation measurement
97	among participants aged 50 years or older with available biospecimens and included a random sample of
98	approximately half of eligible non-Hispanic White participants and all eligible participants from other
99	ethnic and racial groups (<i>i.e.</i> , non-Hispanic Black, Mexican American, other Hispanic, and other race). ³⁵
100	DNA was extracted from whole blood and stored at -80°C until DNA methylation measurement. DNA
101	underwent bisulfite conversion and DNA methylation was measured using the Illumina Infinium
102	MethylationEPIC BeadChip v1.0 (Illumina, San Diego, CA, US) following the manufacturer's
103	recommendations. The MethylationEPIC BeadChip interrogates over 850,000 CpG dinucleotides. ³⁶ Raw
104	DNA methylation data were imported into R for preprocessing and quality control (QC). The

preprocessing and QC pipeline included color correction, background subtraction, and removal of outlier
samples based on median intensity values.

107 *Epigenetic age and biomarkers*

Epigenetic age estimates and aging biomarkers were provided by NHANES.³⁵ Prior to biomarker 108 109 calculation, DNA methylation data were normalized using the beta mixture quantile (BMIQ) method, which adjusts for probe type bias.³⁷ For the calculation of the Horvath1, Horvath2, PhenoAge, and 110 111 GrimAge2 clocks, a modified BMIQ method was applied using a gold standard based on the largest training dataset in the Horvath1 clock.²³ The epigenetic age estimates or scores were calculated for each 112 113 participant using the respective published coefficients and intercepts. We focused on widely studied and 114 established epigenetic aging biomarkers including three first-generation clocks (*i.e.*, trained to estimate chronological age): Horvath1,²³ Horvath2,²⁴ and Hannum;³¹ two second-generation clocks (*i.e.*, trained to 115 116 predict aging-related phenotypes, mortality, and morbidity risk): PhenoAge²⁵ and GrimAge2;²⁶ a third-117 generation clock (*i.e.*, trained to measure the rate of change of epigenetic age): Dunedin Pace-of-Aging (DunedinPoAm);²⁸ and telomere length (DNAmTL).³² GrimAge2 is an updated version of the GrimAge 118 119 biomarker of mortality risk, which includes training on additional DNA methylation-based estimates of 120 plasma proteins (high sensitivity C-reactive protein (CRP) and hemoglobin A1C). Due to the high 121 correlation between GrimAge and GrimAge2 in NHANES (r = 0.99), we chose to only analyze 122 GrimAge2. In addition to GrimAge2 calculations, available NHANES data also includes DNA 123 methylation-based estimates of plasma proteins used in the calculation of this clock.

124 Nutritional biochemistries

Methods for nutritional biochemistries are described on the NHANES website with the respective data releases.^{38,39} Briefly, serum folate and B12 concentrations were measured using the Quantaphase II Folate/vitamin B12 radioassay kit (Bio-Rad Laboratories, Hercules, CA, US).³⁸ RBC folate was measured by diluting samples in ascorbic acid in water and incubating or freezing to hemolyze RBCs. Samples were diluted again in protein diluent and RBC folate was measured using methods analogous to serum folate. Plasma Hcy was measured using the Abbott Homocysteine assay, a fluorescence polarization

immunoassay, and the Abbott IMX analyzer (Abbott Diagnostics, Chicago, IL, US). MMA was extracted
from plasma or serum with a strong anion exchange resin, and concentrations were measured by gas
chromatography and a mass selective detector.

134 Covariates

135 Demographic, socioeconomic, anthropometric measures, and self-reports of health-related 136 behaviors were collected as part of the NHANES questionnaire and physical examination. As defined by 137 NHANES, chronological age at the time of the screening interview was calculated from reported date of 138 birth. In the case of missing date of birth, reported age in years was used to impute date of birth. Self-139 reported race and ethnicity were classified as Non-Hispanic White, Mexican American, other Hispanic, 140 Non-Hispanic Black, or other race including Multiracial. Smoking status was based on the Smoking and 141 Tobacco Use Questionnaire Section and classified as never (not having smoked at least 100 cigarettes in 142 life), former (having smoked at least 100 cigarettes in life but not currently smoking), or current (having 143 smoked at least 100 cigarettes in life and currently smoking every day or some days). Alcohol intake in 144 average number of drinks per day in the last 12 months was calculated from the Alcohol Use 145 Questionnaire Section. Occupational status was obtained from the Occupation Questionnaire Section and 146 classified as white-collar and professional work, white-collar and semi-routine work, blue-collar and high-skill work, blue-collar and semi-routine work, or no work as described.⁴⁰ Education level was 147 148 classified as less than high school, high school diploma (including GED), or more than high school. The 149 poverty to family income ratio (PIR) was based on the Department of Health and Human Services' (HHS) 150 poverty guidelines and calculated as the family income divided by the poverty guidelines for family size 151 and year. Body mass index (BMI) in kg/m^2 was calculated from height and weight measurements 152 collected by trained technicians during examinations.

Data on selected protein concentrations measured in blood were also available in NHANES.
Serum β-2 microglobulin (B2M) concentrations were measured with a B2M immunoassay and serum
cystatin C concentrations were measured with a Cystatin C immunoassay on an automated multi-channel
analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, US).⁴¹ CRP concentrations were measured

using latex-enhanced nephelometry.^{42,43} Glycohemoglobin (hemoglobin A1C) concentrations in plasma
were measured using an HPLC-based automated glycohemoglobin analyzer (Primus, Kansas City, MO,
US).^{44,45}

160 Statistical analyses

Among 2,532 participants with epigenetic age estimates, we excluded those with a recorded age of \geq 85 years (*n* = 130) or with a mismatch between recorded sex and a DNA methylation-based sex estimate (*n* = 56) (**Supplementary Figure 1**). We calculated epigenetic age deviation (EAD), also known as epigenetic age acceleration,⁴⁶ as the residuals of regressing chronological age in years on epigenetic age. DunedinPoAm was analyzed centered and scaled. Blood cell type proportions (CB8+ T cells, CD4+ T cells, neutrophils, monocytes, B cells, and natural killer cells) were estimated using regression calibration⁴⁷ based on IDOL probe selection.^{48,49}

168 Descriptive statistics before survey weighting were calculated as means and standard deviations 169 (SDs) for continuous variables and frequencies and proportions for categorical variables. We evaluated 170 performance of the epigenetic aging biomarkers by calculating correlations and median absolute errors 171 (MAEs) between chronological age and estimated epigenetic age. Survey weights were provided with the NHANES epigenetic biomarkers dataset.³⁵ The survey design was specified using the *Survey* R package 172 173 for statistical analyses.^{50,51} To preserve the study design, the survey design was specified prior to dropping 174 participants \geq 85 years old and sex mismatches. Correlations between OCM-related micronutrient 175 concentrations (serum folate, RBC folate, B12, Hcy, and MMA) were calculated using the svycor 176 function using the bootstrap procedure in the *itools* R package.⁵² 177 We evaluated associations of OCM-related micronutrients and biomarkers with epigenetic aging 178 biomarkers (EAD residuals or DunedinPoAm) using survey-design weighted generalized linear regression models. Analyses were conducted using the *svyglm* function in the *Survey* R package.^{50,51} The 179 180 concentrations of serum folate, RBC folate, B12, Hcy, and methylmalonic acid were log₂ transformed to 181 reduce the influence of outliers and meet model assumptions. Primary models were adjusted for potential

182 confounders and precision variables identified *a priori*: chronological age, chronological age², sex, race 183 and ethnicity, smoking status, education level, occupation, and PIR. 184 Smoking and alcohol intake may be associated with concentrations of OCM-related compounds due to lifestyle and dietary factors. In addition, smoking⁵³ and alcohol⁵⁴ may act as folate antagonists by 185 186 affecting the absorption, metabolism, and maintenance of circulating levels. In our NHANES study 187 sample, we found that current smoking status compared to never smoking was negatively associated with 188 the concentrations of serum folate, RBC folate, and MMA and positively associated with the concentration of Hcy (p < 0.05; Supplemental Tables 1 and 2), consistent with previous studies.^{55,56,56} 189 190 Alcohol intake was negatively associated with B12 concentration and positively associated with Hcy 191 concentration (p < 0.05). In addition, former and current smokers reported greater alcohol intake 192 (drinks/day, never smokers = 0.2; former smokers = 0.4; current smokers = 0.8; p < 0.001) 193 (Supplemental Table 1). Therefore, we also conducted analyses adjusting for smoking status (former or 194 current smoking vs. never) and alcohol intake to evaluate if associations of OCM-related compounds and 195 epigenetic aging biomarkers were independent of these exposures. When adjusting for smoking or alcohol 196 alone, we saw the largest change in effect sizes with inclusion of smoking in the model (data not shown), 197 and, consequently, we also tested for interactions between the concentrations of OCM-related compounds 198 and smoking status by conducting stratified analyses and including an interaction term in unstratified 199 analyses. 200 We further added log₂-transformed cystatin C concentration, an indicator of renal function, as a 201 covariate to the models. Elevated homocysteine can impair renal function, and, in turn, impaired renal function increases the risk of cardiovascular disease.⁵⁷ In addition, poor renal function has been associated 202 with increased serum folate and RBC folate concentration in a previous study in NHANES.⁵⁸ 203 204 Considering conflicting evidence of the relationship between excess folate and B12 and adverse

health outcomes, including cancer progression and cognition,^{59–63} we tested for non-linear associations

- using fully adjusted models with folate tertiles (serum folate: < 11.2, ≥ 11.2 and < 17.6, and ≥ 17.6
- 207 ng/mL; RBC folate: < 250, ≥ 250 and < 352, and ≥ 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398, ≥ 398 and < 352 ng/mL RBC) and B12 tertiles (< 398 and < 352 ng/mL RBC) and B12 tertiles (< 398 and < 352 ng/mL RBC) and > 352

208 583, and \geq 583 pg/mL). We also conducted analyses with the dichotomous variable hyperhomocysteinemia (Hcy concentration > 15 umol/L)⁶⁴ vs. not. 209 210 To evaluate if individual GrimAge2 components were contributing to the associations with 211 GrimAge2 EAD, we conducted adjusted analyses of serum folate, RBC folate, and homocysteine 212 concentrations using GrimAge2 components (plasma protein surrogates and smoking pack years) as the 213 outcomes. We conducted complementary analyses for proteins with laboratory measures, if available 214 (B2M, cystatin C, CRP, and hemoglobin A1C). 215 We performed sensitivity analyses adjusting for cell type proportions to distinguish between 216 intrinsic aging (*i.e.*, intracellular) and extrinsic aging (*i.e.*, reflecting age-related changes in cell type 217 proportions). Our primary analyses were conducted using complete cases. We also conducted sensitivity 218 analyses following imputation of missing covariate data. Data were imputed with multiple imputation by 219 chained equations using the *MICE* R package⁶⁵ and 5 iterations. Following imputation, we reanalyzed 220 associations of OCM-related micronutrients and compounds with aging biomarkers using fully adjusted 221 weighted generalized linear regression models and pooled estimates from each imputed dataset with the 222 pool function. 223 We used 95% confidence intervals (95% CIs) to evaluate precision of associations and p < 0.05 to 224 test for statistical significance. All analyses were conducted in R version 4.4.1.⁶⁶ We used the STROBEnut checklist when writing our report.⁶⁷ 225 226 227 Results 228 Epigenetic aging biomarker and nutritional biomarker data were available for 2,346 participants. 229 Participant demographic characteristics and concentrations of OCM-related nutrients and compounds, 230 prior to survey weighting, are shown in **Table 1**. Participants had a mean (SD) chronological age of 65.1 231 (9.3) years, and approximately half (51.2%) of participants were male. Nearly all participants were folate

replete; 5 participants had serum folate concentrations less than or equal to the reference value of 3

233 ng/mL.⁶⁸ Twenty-one (0.9%) participants were classified as B12 deficient (concentration <150 pg/mL)

and 329 (14.0%) were classified as B12 insufficient (concentration < 300 pg/mL).⁸

- Hyperhomocysteinemia was more common, with 192 (8.2%) participants having Hcy concentration > 15
 umol/L.⁶⁴
- 237 Participant characteristics stratified by smoking status are shown in **Supplemental Table 1**. 238 Compared to never smokers, former smokers were more likely to be male and had greater alcohol intake, 239 lower median B12 concentration, and greater median Hcy concentration; current smokers were more 240 likely to be male and younger, and had lower BMI, greater alcohol intake, lower median concentration of 241 serum folate and RBC folate, and higher median concentration of Hcy. 242 All first- and second-generation clocks were strongly correlated with chronological age, with 243 Pearson correlation coefficients ranging from r = 0.76 for PhenoAge to r = 0.87 for Horvath2 (p < 0.001) 244 (Supplemental Figure 2). The Horvath2 clock had the lowest MAE compared to chronological age (2.71 245 years) whereas PhenoAge had the largest MAE (10.33 years). As expected, DunedinPoAm was very 246 weakly correlated with chronological age (r = 0.04; p = 0.049) and DNAmTL was negatively correlated 247 with chronological age (r = -0.58; p < 0.001). 248 After survey weighting, there were moderate correlations of serum folate with RBC folate and 249 Hey with MMA (r = 0.51 and 0.50, respectively; p < 0.001) (Supplemental Figure 3). Serum folate was 250 significantly but weakly associated with B12 (r = 0.04; p = 0.034), Hey (r = -0.07; p = 0.002), and MMA 251 (r = 0.05; p = 0.014). There were also weak correlations of RBC folate with Hcy (r = -0.09; p < 0.001)252 and B12 with Hcy (r = -0.05; p < 0.001) and MMA (r = -0.02; p < 0.001). 253 Associations of folate and B12 with epigenetic aging biomarkers 254 Figure 2 and Supplementary Table 3 show results of our analyses of promoters of OCM (*i.e.*, 255 serum and RBC folate and B12). Our primary analyses used weighted generalized linear regression
- 256 models adjusted for chronological age, chronological age², sex, race and ethnicity, BMI, education level,
- 257 occupation, and PIR. We additionally adjusted for self-reported smoking status, alcohol intake, and
- 258 cystatin C, an indicator of renal function.

259 Each doubling of serum folate concentration was associated with -0.82 years (95% CI = -1.40, -260 0.23; p = 0.010) lower GrimAge EAD, -0.13 SDs (95% CI = -0.22, -0.03; p = 0.015) lower 261 DunedinPoAm, and 0.02 kb (95% CI = 0.00, 0.04; p = 0.037) greater DNAmTL EAD. After adjusting for 262 smoking status and alcohol intake, serum folate concentration modeled continuously was not significantly 263 associated with any epigenetic aging biomarker (p > 0.05); however, the third vs. first tertile of serum 264 folate was positively associated with DNAmTL EAD (B (95% CI) = 0.04 kb (0.01, 0.07); p = 0.043) 265 (Supplemental Table 4). After adjusting for cystatin C, serum folate was associated with GrimAge2 266 EAD (B (95% CI) = -0.46 years per doubling (-0.91, -0.01); p = 0.047), but not DunedinPoAm or 267 DNAmTL EAD. In analyses stratified by smoking status, serum folate concentration was negatively 268 associated with GrimAge2 EAD (B (95% CI) = -1.42 years per doubling (-2.50, -0.34); p = 0.014) and 269 DunedinPoAm (B (95% CI) = -0.24 SDs (-0.45, -0.03); p = 0.031) among current smokers (*i.e.*, the group 270 with significantly lower serum folate concentration), but not among never or former smokers, although 271 the serum folate and smoking interaction term was not significant (Supplemental Table 5). 272 Before controlling for smoking status and alcohol intake, RBC folate concentration was 273 positively associated with PhenoAge EAD (B = 0.88 years per doubling; 95% CI = -0.10, 1.85; p = 0.07), 274 although this association did not reach statistical significance (Figure 2 and Supplementary Table 3). 275 With adjustment for smoking and alcohol, the association of RBC folate concentration and PhenoAge 276 EAD increased (B = 1.06 years per doubling; 95% CI = -0.03, 2.14; p = 0.06), and there was a trend 277 toward a positive association with GrimAge2 EAD (B = 0.59 years per doubling; 95% CI = -0.08, 1.26; p 278 = 0.08), and DunedinPoAm (B = 0.11 SDs per doubling; 95% CI = -0.08, 1.26; p = 0.08). RBC folate 279 concentration among former smokers were not significantly different from those of never smokers. 280 However, among former smokers, RBC folate concentration was significantly associated with GrimAge2 281 EAD (B = 1.15 years per doubling; 95% CI = 0.40, 1.89; p = 0.006) and DunedinPoAm (B = 0.15 SDs per 282 doubling; 95% CI = 0.00, 0.30; p = 0.047) (Supplemental Table 5). Associations were not significant 283 among never or current smokers; however, the interaction term was not significant.

- B12 concentration and tertiles were not significantly associated with any epigenetic aging
- 285 biomarker (p > 0.05).
- 286 Associations of homocysteine and methylmalonic acid with epigenetic aging biomarkers
- Associations of markers of OCM deficiencies (*i.e.*, Hcy and MMA) with epigenetic aging
- biomarkers are shown in Figure 3 and Supplementary Table 3. Hey concentration was positively
- associated with PhenoAge EAD (B (95% CI) = 1.05 years per doubling (0.06, 2.04); p = 0.039),
- 290 GrimAge2 EAD (B (95% CI) = 1.93 years per doubling (1.16, 2.71); p < 0.001), and DunedinPoAm (B
- 291 (95% CI) = 0.26 SDs per doubling (0.10, 0.41); p = 0.003). After adjusting for smoking status and alcohol
- 292 intake, associations of Hcy with GrimAge2 EAD and DunedinPoAm remained significant but attenuated
- 293 (GrimAge2 EAD: B (95% CI) = 1.32 years per doubling (0.69, 1.94); p = 0.001 and DunedinPoAm: B
- 294 (95% CI) = 0.14 SDs per doubling (0.00, 0.27); p = 0.048). With cystatin C adjustment, the association
- with GrimAge2 EAD was further attenuated (B (95% CI) = 0.82 years per doubling (0.05, 1.60); p =
- 296 0.040), and the association with DunedinPoAm was null. Hyperhomocysteinemia vs. normal Hcy range
- 297 was associated with greater PhenoAge EAD (B (95% CI) = 1.97 years (0.54, 3.40); p = 0.012) and
- 298 GrimAge2 EAD (*B* (95% CI) = 2.00 years (0.83, 3.17); *p* = 0.003) (**Supplemental Table 4**). In stratified
- analyses, Hcy concentration was significantly and positively associated with GrimAge2 EAD among
- former smokers (B (95% CI) = 1.47 years year doubling (0.47, 2.48); p = 0.008) and current smokers (B
- 301 (95% CI) = 1.76 years per doubling (0.50, 3.03); p = 0.010), but not among never smokers (B (95% CI) =
- 302 0.82 years per doubling (-0.11, 1.75); p = 0.08), with significant interaction between Hcy concentration
- 303 and former vs. never smoking ($p_{int} = 0.027$) (Figure 4 and Supplemental Table 5).
- 304 MMA concentration was not associated with the epigenetic aging biomarkers in our primary
 305 analyses. However, among former smokers, MMA was positively associated with PhenoAge EAD (*B*
- 306 (95% CI) = 0.88 years per doubling (0.16, 1.60); p = 0.021).
- 307 Associations with GrimAge2 components

GrimAge2 is calculated as a weighted linear combination of DNA methylation-based surrogates
 for 9 plasma proteins and smoking pack years. Therefore, to evaluate if individual components of

310 GrimAge2 were driving the associations of serum folate, RBC folate, and Hcy with GrimAge2 EAD, we 311 evaluated associations of each of the components separately. For serum folate concentration, only the 312 association with the surrogate for smoking pack years was significant, even after adjusting for self-313 reported smoking status (Z-score scale) (B (95% CI) = -0.07 per doubling (-0.13, -0.01); p = 0.033) 314 (**Table 2**). RBC folate concentration was significantly associated with GDF15 (B (95% CI) = 0.07 per 315 doubling (0.01, 0.03); p = 0.023, PAI1 (B (95% CI) = 0.14 per doubling (0.01, 0.27); p = 0.038), and 316 $\log(\text{CRP})$ (B (95% CI) = 0.23 per doubling (0.11, 0.35); p = 0.002). Hey concentration was positively 317 associated with five GrimAge2 components: B2M (B (95% CI) = 0.14 per doubling (0.06, 0.22); p =318 0.002), Cystatin C (B (95% CI) = 0.09 per doubling (0.02, 0.16); p = 0.021), TIMP1 (B (95% CI) = 0.08 319 per doubling (0.03, 0.13); p = 0.005, ADM (B (95% CI) = 0.17 per doubling (0.06, 0.29); p = 0.007), and 320 smoking pack years (B (95% CI) = 0.15 per doubling (0.02, 0.28); p = 0.030). 321 Laboratory measures for serum B2M and cystatin C concentrations, CRP concentration, and 322 hemoglobin A1C were also available in these NHANES cycles. Within our sample, all GrimAge2 323 components were moderately correlated with their measured counterparts (without survey weighting: 324 B2M: r = 0.25; cystatin C: r = 0.22; CRP: r = 0.28; hemoglobin A1C: r = 0.50; p < 0.001). Therefore, we 325 also tested if Hcy concentration was significantly associated with measured values (Table 2). Overall, 326 results were consistent with those of the GrimAge2 components. However, RBC folate concentration was 327 positively associated log₂(cystatin C) (B (95% CI) = 0.11 per doubling (0.01, 0.21); p = 0.029) 328 Hey concentration was also associated with lower log_2 (hemoglobin A1C) (B (95% CI) = -0.04 per 329 doubling (0.06, 0.02)). 330 Sensitivity analyses 331 In sensitivity analyses adjusting for estimated cell type proportions, results were similar to those 332 of our primary analyses but attenuated (Supplemental Table 6). The association of Hcy concentration

333 with GrimAge2 EAD remained significant (B (95% CI) = 1.13 years per doubling (0.52, 1.75); p =

334 0.007). Analyses using imputed covariate data were also largely consistent with our primary analyses

335 (Supplemental Table 7). A doubling in Hcy concentration was associated with 1-year greater PhenoAge

336 EAD (95% CI = 0.13, 1.87, p = 0.029), 1.44 years greater GrimAge2 EAD (95% CI = 0.87, 2.00, p

337 < 0.001), and 0.17 SD greater DunedinPoAm (95% CI = 0.04, 0.31, p = 0.019).

338

339 Discussion

340 We tested associations of OCM-related biomarkers with epigenetic aging biomarkers in 341 NHANES, a nationally representative sample of adults in the US where DNA methylation was assayed on 342 the population age 50 and older. The strongest and most robust associations were with EAD measured by 343 second generation clocks. We provide evidence that greater concentration of Hcy, an indicator of OCM 344 deficiencies, is associated with greater GrimAge2 EAD and DunedinPoAm. For each doubling of Hcy 345 concentration, GrimAge2 EAA was 1.32 years greater and DunedinPoAm was 0.14 SDs greater. This 346 association persisted after adjustment for smoking status and alcohol intake - folate antagonists and 347 behaviors associated with poor diet quality. We also found that serum folate concentration was 348 significantly associated with lower GrimAge2 EAD and DunedinPoAm and greater DNAmTL EAD; 349 however, associations were imprecise after adjusting for smoking status and alcohol intake. Similarly, the 350 association of Hcy concentration with greater PhenoAge EAD was attenuated after controlling for smoking and alcohol. It is known that smoking and alcohol intake are associated with increased EAD.⁶⁹⁻⁷¹ 351 352 and changes in OCM-related biomarkers may be one mechanism through which this occurs. 353 While our study did not directly investigate clinical endpoints, our findings support previous 354 research linking elevated Hcy to adverse age-related health outcomes, including cognitive impairment and decline.¹⁸ cardiovascular disease incidence and¹⁷ mortality¹⁷ and all-cause mortality.¹⁷ Particularly 355 356 relevant to the current study, in NHANES 1999-2006, Hcy has been associated with increased all-cause mortality and CVD mortality.⁷² GrimAge2 is an epigenetic clock developed to estimate mortality risk.²⁶ 357 358 GrimAge2 is calculated as the weighted linear combination of sex, age, and DNA methylation surrogates 359 for smoking pack years and 9 plasma proteins (adrenomedullin (ADM), B2M, cystatin C, growth 360 differentiation factor 15 (GDF-15), leptin, CRP, hemoglobin A1C, plasminogen activation inhibitor 1

361 (PAI-1), and tissue inhibitor metalloproteinase 1 (TIMP-1)). In addition to the overall positive association

362 of Hcy concentration and hyperhomocysteinemia with GrimAge2 EAD, we found that Hcy was 363 associated with greater DNA methylation surrogates of B2M (a biomarker of cardiovascular disease, 364 kidney function, and inflammation⁷³), cystatin C (a biomarker of kidney function⁷⁴), TIMP1 (a regulator of cell growth⁷⁵ and inflammation⁷⁶), ADM (a vasodilator and prognostic marker in CVD⁷⁷), and smoking 365 366 pack years. In addition, analyses of directly measured protein levels were consistent with our findings on 367 epigenetic estimates. In stratified analyses, we found evidence that Hcy has a stronger association with 368 GrimAge2 EAD among former and current smokers compared to never smokers. 369 DunedinPoAm is an epigenetic biomarker that estimates the rate of change of 18 biomarkers 370 capturing organ-system integrity and was trained on data over a 12-year span.²⁸ The biomarkers included 371 both blood biochemistries (e.g., hemoglobin A1C, CRP, lipoprotein (a), HDL cholesterol) and functional 372 and cardiometabolic measurements (e.g., BMI, cardiorespiratory fitness, pulmonary function). Greater 373 DunedinPoAm has been associated with greater physical and cognitive decline, morbidity, and 374 mortality.²⁸ In our study, Hcy was positively associated with DunedinPoAm and was robust to smoking 375 and alcohol adjustment. However, this association was null after adjustment for cystatin C, suggesting 376 that kidney function may be involved in the mechanism linking Hcy to DunedinPoAm. 377 We also found significant negative associations of serum folate with GrimAge2 EAD and 378 DunedinPoAm before adjusting for smoking and alcohol. After smoking and alcohol intake adjustment, 379 associations remained negative but did not reach statistical significance. Stratified analyses suggested that 380 folate may be protective against increased DunedinPoAm and GrimAge2 EAD among smokers, although 381 we did not find significant Hcy and smoking interaction. However, our analyses of smoking-specific 382 effects are limited by small sample size (N = 811 never smokers, N = 732 former smokers, and N = 287383 current smokers with complete serum folate and complete covariate data). 384 In contrast to our hypothesis that higher folate concentration would be protective against 385 epigenetic aging, we observed a trend toward a positive association between RBC folate concentration 386 and epigenetic aging measured by second generation clocks and DunedinPoAm. Although these 387 associations did not reach statistical significance in the NHANES sample overall, associations of RBC

388 folate with GrimAge2 EAD and DunedinPoAm were positive and significant among former smokers. 389 Serum folate and RBC folate are both indicators of folate deficiency and were significantly correlated in 390 our study. Although RBC folate is reflective of long-term folate status, measurement of RBC folate is 391 more costly, has greater analytical variability, and has not shown diagnostic value in clinical settings beyond that of serum folate concentrations.⁷⁸ We hypothesize that RBC folate concentration may also 392 393 capture pathophysiological changes beyond serum folate measurements. Red blood cell abnormalities, 394 including megaloblastic anemia, macrocytosis, and increased mean cell volume and red cell distribution 395 width, are associated with folate and B12 deficiencies.⁷⁹ However, cell distribution width has also been positively associated with inflammatory markers and oxidative stress,^{80,81} and RBCs may be involved in 396 inflammatory processes due to their cytokine binding capacity.⁸² The second generation clocks and 397 398 DunedinPoAm are trained on biomarkers of inflammation, such as CRP (PhenoAge, GrimAge2, 399 DunedinPoAm), white blood cell count (DunedinPoAm), mean cell volume (PhenoAge), and red blood 400 cell distribution width (PhenoAge), and therefore these clocks may be sensitive to inflammatory-related 401 variations in RBCs. Furthermore, RBC folate concentration was positively associated with cystatin C, both in our study and a previous analysis of NHANES.⁵⁸ The relationship between RBC folate and the 402 403 second-generation clocks may also be reflecting impaired renal function related in aging and chronic 404 disease development. These explanations are supported by our analyses of RBC folate concentration with 405 the GrimAge2 components and measured proteins related to inflammation and renal function. 406 Associations of plasma folate, B12, B6, and Hcy with Horvath1 EAD, PhenoAge EAD, and 407 GrimAge EAD have previously been investigated in the Veterans Affairs Normative Aging Study, a cohort of older community-dwelling men (N = 715).⁸³ This study used Bayesian Kernel Machine 408 409 Regression (BKMR), a mixture approach that allows for the selection of statistically important 410 independent variables. B6 was identified as important for predicting PhenoAge EAD with a negative 411 direction of association, and folate was identified as important for predicting GrimAge EAD and 412 PhenoAge EAD with positive directions of associations. Our findings were not consistent with these 413 results, possibly due to differences in populations studied and analytical differences. BKMR produces

414 single-exposure effect estimates holding all other exposures at a fixed percentile. Given the complex 415 relationship between nutritional factors and OCM metabolites, including an antagonistic relationship 416 between one-carbon donors and Hcy, it may be difficult to interpret effects of folate when B12, B6, and 417 Hcy are evaluated at a common percentile. 418 Associations of OCM-related compounds and epigenetic aging have also been analyzed in a 419 supplementation study among older adults with mild cognitive impairment (N = 217). This study reported 420 a positive correlation between baseline plasma Hcy and rate of aging (*i.e.*, epigenetic age divided by chronological age) measured by Horvath2, Hannum, Zhang,⁸⁴ DunedinPACE,⁸⁵ and Index, a 421 commercially available epigenetic clock (Elysium Health, New York, NY, US).⁸⁶ Furthermore, this study 422 423 found evidence that supplementation with a B-vitamin complex (B6, B12, and folic acid) may decrease 424 epigenetic age among individuals with hyperhomocysteinemia. 425 Understanding the relationship between OCM-related compounds and epigenetic aging 426 biomarkers may help advance the study of nutrition and aging. Randomized controlled trials have demonstrated that folic acid supplementation lowers homocysteine levels,^{87,88} particularly among 427 428 individuals with low baseline folate.⁸⁹ However, there is less evidence for the downstream health benefits 429 of supplementation with folic acid or other B vitamins. In a 7-year study of women with high risk of CVD 430 (N = 5.442), supplementation with folic acid, B6, and B12 did not significantly reduce the risk of 431 cardiovascular events compared to placebo, despite a significant reduction in homocysteine levels in the

432 treatment group.⁹⁰ Similarly, a 3-year study of adults with cerebral infarction (N = 3,680) found no

433 association of supplementation with folic acid, B6, and B12 with risk of stroke, although lower Hcy was

434 associated with reduced risk of coronary heart disease events.⁹¹ Meta-analyses of folic acid trials

435 concluded that supplementation may reduce the risk of stroke but not mortality 92 , and that reductions in

436 CVD were greatest among individuals with low baseline folate and high reductions in Hcy.⁹³ Inconsistent

437 results have been found for studies of folic acid and B vitamin supplementation and cognitive

438 function;^{94,95} effects may also be modified by baseline nutritional status.⁹⁶ Variation in results of clinical

trials may be due in part to differences in outcomes measured and follow-up time. Although these studies

focused on clinical outcomes, future research may leverage epigenetic aging biomarkers as surrogate endpoints in clinical trials that represent intermediate changes in complex biological pathways.⁹⁷ Our results support the use of some of these biomarkers to test and monitor intervention prior to disease diagnosis or onset.

444 Our study was strengthened by its large sample size and population representative of middle-aged 445 and older adults in the US. We were able to analyze associations with multiple OCM-related compounds 446 and epigenetic clocks to better understand nuances in the relationships between OCM and aging-related 447 biomarkers. However, we were limited by cross-sectional data and the inability to evaluate the effects of 448 changes in OCM status on long-term epigenetic aging and health. A portion of our sample had missing 449 data on covariates and therefore our primary analyses were restricted to complete cases; however, 450 sensitivity analyses using imputed data were consistent. Additionally, we were limited by the nutritional 451 biomarker data available for NHANES. A more comprehensive study including additional OCM-related 452 micronutrients (e.g., choline, betaine and B6) may provide further insights to the relationship between 453 nutrition and epigenetic aging. Our study was also unable to analyze effect modification by genetic 454 factors that affect OCM, such as variants in methylenetetrahydrofolate reductase (MTHFR), the enzyme 455 that processes folate. Multiple testing was not conducted, and therefore some findings might be due to 456 chance. However, we focused on precision of estimates along with pre-hypothesized associations, making 457 such adjustments non-essential. Furthermore, our study was limited to a sample representative of the US 458 adult population, and therefore findings may not be generalizable to populations with different dietary 459 habits, nutritional status, lifestyle habits, and ages.

460

461 Conclusion

As the application of epigenic aging biomarkers becomes more common in research and clinical settings, it is important to understand how intervenable factors, such as nutrition, influence epigenetic aging. In this study of a nationally representative sample of middle-aged and older adults, we found that Hcy concentration is positively associated with epigenetic aging measured by GrimAge2 and

466	DunedinPoAm, particularly among former and current smokers. We also provide evidence that serum
467	folate is associated with lower GrimAge2 EAD and DunedinPoAm and higher DNAmTL EAD. These
468	associations were attenuated after adjusting for smoking status and alcohol intake, suggesting that
469	changes in OCM-related biomarkers may be one mechanism through behavioral factors are related to
470	EAD. Future studies should address the long-term health consequences of OCM-related epigenetic aging
471	and investigate associations in subpopulations such as smokers that may have greater benefit from
472	nutritional interventions.
473	
474	Conflicts of interest: The authors have no conflicts of interest to disclose.
475	
476	Declaration of generative AI in scientific writing: No writing AI assistance was utilized in the writing
477	or production of this manuscript.
478	
479	Data sharing: All datasets analyzed in the current study are publicly available from the NHANES

480 website.

481 **References**

- 482
 483
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
 484
- 485
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
 486
- 487 3. Ducker GS, Rabinowitz JD. One-carbon metabolism in health and disease. Cell Metab
 488 2017; 25:27–42.
- 489
 4. Scott JM, Weir DG. Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry. J Cardiovasc Risk 1998; 5:223–7.
- 491 5. Bozack AK, Saxena R, Gamble MV. Nutritional influences on one-carbon metabolism:
 492 Effects on arsenic methylation and toxicity. Annu Rev Nutr 2018; 38:401–29.
- 493 6. Tejero J, Lazure F, Gomes A. Methylmalonic acid in aging and disease. Trends Endocrinol
 494 Metab 2024; 35:188–200.
- 495 7. Office of Dietary Supplements Folate [Internet]. [cited 2024 Dec 2]; Available from:
 496 https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/
- 497 8. Office of Dietary Supplements Vitamin B12 [Internet]. [cited 2024 Dec 2]; Available
 498 from: https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
- 499 9. Araújo JR, Martel F, Borges N, Araújo JM, Keating E. Folates and aging: role in mild
 500 cognitive impairment, dementia and depression. Ageing Research Reviews 2015; 22:9–19.
- 10. Clarke R, Grimley Evans J, Schneede J, Nexo E, Bates C, Fletcher A, Prentice A, Johnston
 C, Ueland PM, Refsum H, et al. Vitamin B12 and folate deficiency in later life. Age Ageing
 2004; 33:34–41.
- Hazra A, Selhub J, Chao W-H, Ueland P, Hunter, Baron J. Uracil misincorporation into
 DNA and folic acid supplementation. Am J Clin Nutr 2010; 91:160–5.
- 506 12. Reynolds E. Folic acid, ageing, depression, and dementia. BMJ 2002; 324:1512–5.
- 507 13. O'Connor DMA, Scarlett S, De Looze C, O'Halloran AM, Laird E, Molloy AM, Clarke R,
 508 McGarrigle CA, Kenny RA. Low folate predicts accelerated cognitive decline: 8-year
 509 follow-up of 3140 older adults in Ireland. Eur J Clin Nutr 2022; 76:950–7.
- 510 14. Bailey LB, Stover PJ, McNulty H, Fenech MF, Gregory JF, Mills JL, Pfeiffer CM, Fazili Z,
 511 Zhang M, Ueland PM, et al. Biomarkers of nutrition for development—folate review. The
 512 Journal of Nutrition 2015; 145:1636S-1680S.
- 513 15. He H, Shui B. Folate intake and risk of bladder cancer: a meta-analysis of epidemiological
 514 studies. Int J Food Sci Nutr 2014; 65:286–92.

- 515 16. Lentz SR. Mechanisms of homocysteine □ induced atherothrombosis. Journal of Thrombosis
 516 and Haemostasis 2005; 3:1646–54.
- 517 17. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary
 518 heart disease incidence: a systematic review and meta-analysis. Mayo Clin Proc 2008;
 519 83:1203–12.
- 520 18. Smith A, Refsum. Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr
 521 2016; 36:211–39.
- 522 19. Zuliani G, Brombo G, Polastri M, Romagnoli T, Aarons G, Riccetti R, Seripa D, Trentini
 523 A, Cervellati C. High plasma homocysteine levels predict the progression from mild
 524 cognitive impairment to dementia. Neurochem Int 2024; 177:105763.
- 525 20. Zhang G, Liu S, Xu Y, Ma L-Y, Zhang W, Ji Y. Elevated plasma total homocysteine levels
 526 are associated with behavioral and psychological symptoms in dementia with Lewy bodies.
 527 Front Neurosci 2024; 18:1406694.
- Xu Y, Qian X, Zhang M, Liang M. Correlations of cognitive function with serum levels of
 homocysteine, sex hormone binding globulin, and leptin in patients with schizophrenia. Pak
 J Med Sci 2024; 40:2319–23.
- Unadkat SV, Padhi BK, Bhongir AV, Gandhi AP, Shamim MA, Dahiya N, Satapathy P,
 Rustagi S, Khatib MN, Gaidhane A, et al. Association between homocysteine and coronary
 artery disease—trend over time and across the regions: a systematic review and metaanalysis. The Egyptian Heart Journal 2024; 76:29.
- 535 23. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 2013;
 536 14:R115.
- 537 24. Horvath S, Oshima J, Martin GM, Lu AT, Quach A, Cohen H, Felton S, Matsuyama M,
 538 Lowe D, Kabacik S, et al. Epigenetic clock for skin and blood cells applied to Hutchinson
 539 Gilford Progeria Syndrome and ex vivo studies. Aging 2018; 10:1758–75.
- 540 25. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, Hou L, Baccarelli AA,
 541 Stewart JD, Li Y, et al. An epigenetic biomarker of aging for lifespan and healthspan.
 542 Aging 2018; 10:573–91.
- 543 26. Lu AT, Binder AM, Zhang J, Yan Q, Reiner AP, Cox SR, Corley J, Harris SE, Kuo P-L,
 544 Moore AZ, et al. DNA methylation GrimAge version 2. Aging 14:9484–549.
- 545 27. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, Hou L, Baccarelli AA, Li Y,
 546 Stewart JD, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan.
 547 Aging 2019; 11:303–27.
- 548 28. Belsky DW, Caspi A, Arseneault L, Baccarelli A, Corcoran DL, Gao X, Hannon E,
 549 Harrington HL, Rasmussen LJ, Houts R, et al. Quantification of the pace of biological

- aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm.
 eLife 2020; 9:e54870.
- 552 29. Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai P-C, Roetker NS,
 553 Just AC, Demerath EW, Guan W, et al. DNA methylation-based measures of biological
 554 age: meta-analysis predicting time to death. Aging 2016; 8:1844–65.
- 30. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of
 ageing. Nat Rev Genet 2018; 19:371–84.
- 31. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, Klotzle B, Bibikova M, Fan
 J-B, Gao Y, et al. Genome-wide methylation profiles reveal quantitative views of human
 aging rates. Mol Cell 2013; 49:359–67.
- 560 32. Lu AT, Seeboth A, Tsai P-C, Sun D, Quach A, Reiner AP, Kooperberg C, Ferrucci L, Hou
 561 L, Baccarelli AA, et al. DNA methylation-based estimator of telomere length. Aging 2019;
 562 11:5895–923.
- 33. NHANES About the National Health and Nutrition Examination Survey [Internet]. 2024
 [cited 2024 Nov 26]; Available from: https://www.cdc.gov/nchs/nhanes/about_nhanes.htm
- 565 34. CDC. Ethics Review Board Approval [Internet]. National Health and Nutrition
 566 Examination Survey2024 [cited 2024 Dec 19]; Available from:
 567 https://www.cdc.gov/nchs/nhanes/about/erb.html
- 568 35. NHANES 1999-2002 DNA Methylation Array and Epigenetic Biomarkers [Internet]. [cited
 569 2024 Nov 26]; Available from: https://wwwn.cdc.gov/Nchs/Nhanes/DNAm/Default.aspx
- 36. Illumina. Infinium MethylationEPIC BeadChip data sheet. 2015; Available from:
 http://www.illumina.com/content/dam/illuminamarketing/documents/products/datasheets/humanmethylationepic-data-sheet-1070-2015008.pdf
- 574 37. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, Beck S.
 575 A beta-mixture quantile normalization method for correcting probe design bias in Illumina
 576 Infinium 450 k DNA methylation data. Bioinformatics 2013; 29:189–96.
- 577 38. LAB06 [Internet]. [cited 2024 Dec 17]; Available from:
 578 https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/LAB06.htm
- 579 39. L06_B [Internet]. [cited 2024 Dec 17]; Available from:
 580 https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L06_B.htm
- 40. Rehkopf DH, Berkman LF, Coull B, Krieger N. The non-linear risk of mortality by income
 level in a healthy population: US National Health and Nutrition Examination Survey
 mortality follow-up cohort, 1988-2001. BMC Public Health 2008; 8:383.

584 585	41.	SSCARD_A [Internet]. [cited 2024 Dec 19]; Available from: https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/SSCARD_A.htm
586 587	42.	LAB11 [Internet]. [cited 2024 Dec 19]; Available from: https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/LAB11.htm
588 589	43.	L11_B [Internet]. [cited 2024 Dec 19]; Available from: https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L11_B.htm
590 591	44.	LAB10 [Internet]. [cited 2024 Dec 19]; Available from: https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/1999/DataFiles/LAB10.htm
592 593	45.	L10_B [Internet]. [cited 2024 Dec 19]; Available from: https://wwwn.cdc.gov/Nchs/Data/Nhanes/Public/2001/DataFiles/L10_B.htm
594 595 596	46.	Moqri M, Herzog C, Poganik JR, Biomarkers of Aging Consortium, Justice J, Belsky DW, Higgins-Chen A, Moskalev A, Fuellen G, Cohen AA, et al. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell 2023; 186:3758–75.
597 598 599	47.	Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, Wiencke JK, Kelsey KT. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 2012; 13:86.
600 601 602	48.	Koestler DC, Jones MJ, Usset J, Christensen BC, Butler RA, Kobor MS, Wiencke JK, Kelsey KT. Improving cell mixture deconvolution by identifying optimal DNA methylation libraries (IDOL). BMC Bioinformatics 2016; 17:120.
603 604 605 606	49.	Salas LA, Koestler DC, Butler RA, Hansen HM, Wiencke JK, Kelsey KT, Christensen BC. An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray. Genome Biology 2018; 19:64.
607 608 609	50.	Lumley T, Gao P, Schneider B. survey: Analysis of Complex Survey Samples [Internet]. 2024 [cited 2024 Sep 5]; Available from: https://cran.r- project.org/web/packages/survey/index.html
610 611	51.	Lumley T. Analysis of Complex Survey Samples. Journal of Statistical Software 2004; 9:1–19.
612 613	52.	Long JA. jtools: analysis and presentation of social scientific data. Journal of Open Source Software 2024; 9:6610.
614 615	53.	Northrop-Clewes CA, Thurnham DI. Monitoring micronutrients in cigarette smokers. Clinica Chimica Acta 2007; 377:14–38.
616 617	54.	Halsted CH, Villanueva JA, Devlin AM, Chandler CJ. Metabolic interactions of alcohol and folate. J Nutr 2002; 132:2367S-2372S.

- 618 55. Okumura K, Tsukamoto H. Folate in smokers. Clin Chim Acta 2011; 412:521–6.
- 619 56. Gabriel HE, Crott JW, Ghandour H, Dallal GE, Choi S-W, Keyes MK, Jang H, Liu Z,
 620 Nadeau M, Johnston A, et al. Chronic cigarette smoking is associated with diminished
 621 folate status, altered folate form distribution, and increased genetic damage in the buccal
 622 mucosa of healthy adults. Am J Clin Nutr 2006; 83:835–41.
- 57. Hirata A. Is renal function the key to disease risk management in elevated homocysteine
 levels? Hypertens Res 2024; 47:1976–7.
- 58. Wang A, Yeung LF, Ríos Burrows N, Rose CE, Fazili Z, Pfeiffer CM, Crider KS. Reduced
 Kidney Function Is Associated with Increasing Red Blood Cell Folate Concentration and
 Changes in Folate Form Distributions (NHANES 2011–2018). Nutrients 2022; 14:1054.
- 59. Thabet RH, Alessa REM, Al-Smadi ZKK, Alshatnawi BSG, Amayreh BMI, Al-Dwaaghreh
 RBA, Salah SKA. Folic acid: friend or foe in cancer therapy. J Int Med Res 2024;
 52:03000605231223064.
- 60. Morris M, Evans D, Bienias J, Tangney C, Hebert L, Scherr P, Schneider J. Dietary folate
 and vitamin B12 intake and cognitive decline among community-dwelling older persons.
 Arch Neurol 2005; 62:641–5.
- 634 61. Kim Y-I. Folate and cancer: a tale of Dr. Jekyll and Mr. Hyde? Am J Clin Nutr 2018;
 635 107:139–42.
- 636 62. Arendt JFH, Sørensen HT, Horsfall LJ, Petersen I. Elevated vitamin B12 levels and dancer
 637 risk in UK primary care: a THIN Database cohort study. Cancer Epidemiol Biomarkers
 638 Prev 2019; 28:814–21.
- 639 63. Arendt JFH, Farkas DK, Pedersen L, Nexo E, Sørensen HT. Elevated plasma vitamin B12
 640 levels and cancer prognosis: a population-based cohort study. Cancer Epidemiol 2016;
 641 40:158–65.
- 642 64. Son P, Lewis L. Hyperhomocysteinemia [Internet]. In: StatPearls. Treasure Island (FL):
 643 StatPearls Publishing; 2024 [cited 2024 Dec 2]. Available from: 644 http://www.ncbi.nlm.nih.gov/books/NBK554408/
- 645 65. Buuren S van, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations
 646 in R. Journal of Statistical Software 2011; 45:1–67.
- 647 66. R Core Team. R: a language and environment for statistical computing [Internet]. Vienna,
 648 Austria: R Foundation for Statistical Computing; 2015. Available from: https://www.r649 project.org/
- 650 67. Lachat C, Hawwash D, Ocké MC, Berg C, Forsum E, Hörnell A, Larsson C, Sonestedt E,
 651 Wirfält E, Åkesson A, et al. Strengthening the Reporting of Observational Studies in
 652 Epidemiology-Nutritional Epidemiology (STROBE-nut): An Extension of the STROBE
 653 Statement. PLoS Med 2016; 13:e1002036.

- 68. National Institutes of Health. Folate: Dietary Supplement Fact Sheet [Internet]. 2016 [cited
 2016 May 5]. Available from: https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/
- 656 69. Cardenas A, Ecker S, Fadadu RP, Huen K, Orozco A, McEwen LM, Engelbrecht H-R,
 657 Gladish N, Kobor MS, Rosero-Bixby L, et al. Epigenome-wide association study and
 658 epigenetic age acceleration associated with cigarette smoking among Costa Rican adults.
 659 Sci Rep 2022; 12:4277.
- Wang M, Li Y, Lai M, Nannini DR, Hou L, Joehanes R, Huan T, Levy D, Ma J, Liu C.
 Alcohol consumption and epigenetic age acceleration across human adulthood. Aging
 (Albany NY) 2023; 15:10938–71.
- 663 71. Carter A, Bares C, Lin L, Reed BG, Bowden M, Zucker RA, Zhao W, Smith JA, Becker
 664 JB. Sex-specific and generational effects of alcohol and tobacco use on epigenetic age
 665 acceleration in the Michigan longitudinal study. Drug and Alcohol Dependence Reports
 666 2022; 4:100077.
- Liu D, Fang C, Wang J, Tian Y, Zou T. Association between homocysteine levels and
 mortality in CVD: a cohort study based on NHANES database. BMC Cardiovasc Disord
 2024; 24:652.
- Kidney Linder R, Linder R, Linder R, Linder R, Choukroun G, Massy ZA. Plasma beta-2 microglobulin is associated with
 cardiovascular disease in uremic patients. Kidney International 2012; 82:1297–303.
- Ferguson TW, Komenda P, Tangri N. Cystatin C as a biomarker for estimating glomerular
 filtration rate. Curr Opin Nephrol Hypertens 2015; 24:295.
- 675 75. Egea V, Zahler S, Rieth N, Neth P, Popp T, Kehe K, Jochum M, Ries C. Tissue inhibitor of
 676 metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA
 677 and Wnt/β-catenin signaling. PNAS 2012; 109:E309–16.
- 678 76. Schoeps B, Frädrich J, Krüger A. Cut loose TIMP-1: an emerging cytokine in inflammation. Trends Cell Biol 2023; 33:413–26.
- 680 77. Wong HK, Cheung TT, Cheung BMY. Adrenomedullin and cardiovascular diseases. JRSM
 681 Cardiovasc Dis 2012; 1:cvd.2012.012003.
- Farrell C-JL, Kirsch S, Herrmann M. Red cell or serum folate: what to do in clinical practice? Clin Chem Lab Med 2013; 51:555–69.
- 684 79. Aslinia F, Mazza J, Yale S. Megaloblastic anemia and other causes of macrocytosis. Clin
 685 Med Res 2006; 4:236–41.
- 80. Lippi G, Targher G, Montagnana M, Salvagno G, Zoppini G, Guidi G. Relation between
 red blood cell distribution width and inflammatory biomarkers in a large cohort of
 unselected outpatients. Arch Pathol Lab Med 2009; 133:628–32.

689 81. Namazi G, Heidar Beygi S, Vahidi MH, Asa P, Bahmani F, Mafi A, Raygan F. 690 Relationship between red cell distribution width and oxidative stress indexes in patients 691 with coronary artery disease. Rep Biochem Mol Biol 2023; 12:241-50. 692 82. Karsten E, Herbert BR. The emerging role of red blood cells in cytokine signalling and 693 modulating immune cells. Blood Rev 2020; 41:100644. 694 83. Nwanaji-Enwerem J, Colicino E, Gao X, Wang C, Vokonas P, Bover E, Baccarelli A, 695 Schwartz J. Associations of plasma folate and vitamin B6 with blood DNA methylation 696 age: an analysis of one-carbon metabolites in the VA Normative Aging Study. J Gerontol A 697 Biol Sci Med Sci 2021; 76:760-9. 698 84. Zhang Q, Vallerga CL, Walker RM, Lin T, Henders AK, Montgomery GW, He J, Fan D, 699 Fowdar J, Kennedy M, et al. Improved precision of epigenetic clock estimates across 700 tissues and its implication for biological ageing. Genome Med 2019; 11:54. 701 85. Belsky DW, Caspi A, Corcoran DL, Sugden K, Poulton R, Arseneault L, Baccarelli A, 702 Chamarti K, Gao X, Hannon E, et al. DunedinPACE, a DNA methylation biomarker of the 703 pace of aging. eLife 2022; 11:e73420. 704 86. Holmes HE, Valentin RE, Jernerén F, de Jager Loots CA, Refsum H, Smith AD, Guarente 705 L, Dellinger RW, Sampson D. Elevated homocysteine is associated with increased rates of 706 epigenetic aging in a population with mild cognitive impairment. Aging Cell 2024; 707 23:e14255. 708 87. Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, McPartlin J, Scott J. 709 Randomized trial of folic acid supplementation and serum homocysteine levels. Archives of 710 Internal Medicine 2001; 161:695–700. 711 88. van Oort FVA, Melse-Boonstra A, Brouwer IA, Clarke R, West CE, Katan MB, Verhoef P. 712 Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-713 response study. Am J Clin Nutr 2003; 77:1318–23. 714 89. Anderson CAM, Jee SH, Charleston J, Narrett M, Appel LJ. Effects of folic acid 715 supplementation on serum folate and plasma homocysteine concentrations in older adults: a 716 dose-response trial. Am J Epidemiol 2010; 172:932-41. 717 90. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, 718 Manson JE. Effect of folic acid and B vitamins on risk of cardiovascular events and total 719 mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 720 2008; 299:2027-36. 721 91. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, 722 Wang C-H, Stampfer M. Lowering homocysteine in patients with ischemic stroke to 723 prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for 724 Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291:565-75.

- 92. Wang Y, Jin Y, Wang Y, Li L, Liao Y, Zhang Y, Yu D. The effect of folic acid in patients
 with cardiovascular disease: a systematic review and meta-analysis. Medicine 2019;
 98:e17095.
- 94. Durga J, van Boxtel MPJ, Schouten EG, Kok FJ, Jolles J, Katan MB, Verhoef P. Effect of
 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a
 randomised, double blind, controlled trial. Lancet 2007; 369:208–16.
- Ford AH, Flicker L, Alfonso H, Thomas J, Clarnette R, Martins R, Almeida OP. Vitamins
 B12, B6, and folic acid for cognition in older men. Neurology 2010; 75:1540–7.
- van Soest APM, van de Rest O, Witkamp RF, de Groot LCPGM. Positive effects of folic
 acid supplementation on cognitive aging are dependent on ω-3 fatty acid status: a post hoc
 analysis of the FACIT trial. Am J Clin Nutr 2021; 113:801–9.
- P39 97. Biomarkers of Aging Consortium, Herzog CMS, Goeminne LJE, Poganik JR, Barzilai N,
 P40 Belsky DW, Betts-LaCroix J, Chen BH, Chen M, Cohen AA, et al. Challenges and
 P41 recommendations for the translation of biomarkers of aging. Nat Aging 2024; 4:1372–83.
- 742

744 Tables

745

746 Table 1: Participant characteristics (N = 2,346).

747

	n (%) or mean (SD)
Male, n (%)	1,202 (51.2%)
Age at screening, mean (SD)	65.1 (9.3)
Race and ethnicity, n (%)	
Mexican American	681 (29.0%)
Other Hispanic	151 (6.4%)
Non-Hispanic White	922 (39.3%)
Non-Hispanic Black	511 (21.8%)
Other race and Multiracial	81 (3.5%)
BMI (kg/m2), mean (SD)	28.8 (5.8)
Missing, n (%)	84 (3.6%)
Smoking status, n (%)	
Current	374 (15.9%)
Former	903 (38.5%)
Never	1,063 (45.3%)
Missing	6 (0.3%)
Alcohol intake, drinks/day, mean (SD)	0.4 (1.0)
Missing, n (%)	111 (5.0%)
Serum folate (ng/mL), mean (SD)	16.5 (12.2)
Missing, n (%)	1 (<0.01%)
Folate deficiency ^a	5 (<0.01%)
Red blood cell folate (ng/mL RBC), mean (SD)	328 (159)
Missing, n (%)	5 (0.2%)
Vitamin B12 (pg/mL), mean (SD)	734 (4,840)
Missing, n (%)	1 (0.0%)
Vitamin B12 insufficiency, n (%) ^b	329 (14.0%)
Vitamin B12 deficiency, n (%) ^c	21 (0.9%)
Homocysteine (umol/L), mean (SD)	10.1 (5.87)
Missing, n (%)	3 (0.1%)
Hyperhomocysteinemia ^d	192 (8.2%)
Methylmalonic acid (umol/L), mean (SD)	0.2 (0.8)
	7(0.20%)

750 Table 2: Associations of serum folate, red blood cell (RBC) folate, and homocysteine with

GrimAge2 components and measured proteins. Effect estimates (95% confidence intervals (CIs)) and *p*-values are shown for a doubling in homocysteine concentration. GrimAge2 components are expressed on a Z-score scale. Results are from weighted generalized linear regression models adjusted for age, age², sex, race and ethnicity, BMI, smoking status, alcohol intake, education level, occupation, and poverty to income ratio

756

-	GrimAge2 component			Direct Measurement		
	В	95% CI	р	В	95% CI	р
Serum Folate ^a						
GDF15	0.00	(-0.06, 0.05)	0.92	$0.02^{\ d}$	(-0.07, 0.11)	0.66
B2M	-0.04	(-0.12, 0.04)	0.25	0.04 ^e	(-0.03, 0.12)	0.22
Cystatin C	-0.01	(-0.06, 0.04)	0.68			
TIMP1	-0.02	(-0.05, 0.02)	0.30			
ADM	-0.05	(-0.13, 0.03)	0.21			
PAI1	0.03	(-0.07, 0.13)	0.52			
Leptin	-0.01	(-0.04, 0.03)	0.69			
log(CRP)	-0.01	(-0.14, 0.11)	0.84	$-0.08^{\text{ f}}$	(-0.22, 0.06)	0.23
log(Hemoglobin A1C)	0.00	(-0.07, 0.06)	0.90	0.01 ^g	(0.00, 0.02)	0.12
Smoking pack years	-0.07	(-0.13, -0.01)	0.033			
RBC Folate ^b						
GDF15	0.07	(0.01, 0.13)	0.023			
B2M	0.02	(-0.06, 0.1)	0.57	0.11 ^d	(0.00, 0.22)	0.06
Cystatin C	0.05	(-0.02, 0.12)	0.12	0.11 ^e	(0.01, 0.21)	0.029
TIMP1	0.04	(0.00, 0.09)	0.06			
ADM	0.05	(-0.03, 0.14)	0.21			
PAI1	0.14	(0.01, 0.27)	0.038			
Leptin	0.07	(0.00, 0.13)	0.06			
log(CRP)	0.23	(0.11, 0.35)	0.002	0.19 ^f	(-0.01, 0.38)	0.06
log(Hemoglobin A1C)	0.03	(-0.08, 0.14)	0.51	-0.01 ^g	(-0.03, 0.01)	0.35
Smoking pack years	0.00	(-0.10, 0.09)	0.95			
Homocysteine ^c						
GDF15	0.04	(-0.09, 0.17)	0.55		-	
B2M	0.14	(0.06, 0.22)	0.002	0.39 ^d	(0.29, 0.49)	<0.001
Cystatin C	0.09	(0.02, 0.16)	0.021	0.32 ^e	(0.24, 0.39)	<0.001
TIMP1	0.08	(0.03, 0.13)	0.005		-	
ADM	0.17	(0.06, 0.29)	0.007		-	
PAI1	0.10	(-0.05, 0.24)	0.18		-	
Leptin	0.00	(-0.07, 0.08)	0.99		-	
log(CRP)	0.14 ^a	(-0.02, 0.29)	0.09	-0.13 ^f	(-0.37, 0.11)	0.28
log(Hemoglobin A1C)	0.09 ^a	(-0.04, 0.22)	0.17	-0.04 ^g	(-0.06, -0.02)	0.002
Smoking pack years	0.15	(0.02, 0.28)	0.030		· · · ·	

a. N = 1,832 for GrimAge2 components; N = 1,812 for B2M concentration; N = 1,816 for cystatin C concentration; N = 1,832 for CRP concentration; N = 1,832 for hemoglobin A1C concentration. b. N = 1,830 for GrimAge2 components; N = 1,813 for B2M concentration; N = 1,815 for cystatin C concentration; N = 1,830 for CRP concentration; N = 1,830 for hemoglobin A1C concentration. c. N = 1,830 for GrimAge2 components; N = 1,812 for B2M concentration; N = 1,816 for cystatin C concentration; N = 1,830 for GRP concentration; N = 1,830 for concentration; N = 1,830 for CRP concentration; N = 1,830 for concentration; N = 1,816 for cystatin C concentration; N = 1,830 for CRP concentration; N = 1,830 for hemoglobin A1C concentration. d. $\log_2(\text{serum B2M in mg/L})$. e. $\log_2(\text{serum cystatin C in mg/L})$. f. $\log_2(\text{CRP in mg/dL})$. g. $\log_2(\text{plasma hemoglobin A1C \%})$.

758 Figure legends

759

760 **Figure 1:** One-carbon metabolism. Compounds included in this study are shown in orange.

761

762 Figure 2: Associations of promoters of one-carbon metabolism (OCM) with epigenetic aging

biomarkers. Effect estimates (95% confidence intervals (CIs)) and *p*-values are shown for a doubling in

concentration of each compound. Results are from weighted generalized linear regression models
 adjusted for age, age², sex, race and ethnicity, BMI, education level, occupation, and poverty to income

ratio. Effect estimates for Horvath1, Horvath2, Hannum, PhenoAge, and GrimAge2 EAD are in years;

- refect estimates for DunedinPoAm are in standard deviations; and effect estimates for DNAmTL EAD are
- in kilobases. RBC = red blood cell; EAD = epigenetic age deviation. * p < 0.05; ** p < 0.01; *** p <
- 769 0.001.

770

771 Figure 3: Associations of markers of one-carbon metabolism (OCM) deficiencies with epigenetic

aging biomarkers. Effect estimates (95% confidence intervals (CIs)) and *p*-values are shown for a

doubling in concentration of each OCM-related compound. Results are from weighted generalized linear

regression models adjusted for age, age², sex, race and ethnicity, BMI, education level, occupation, and

poverty to income ratio. Effect estimates for Horvath1, Horvath2, Hannum, PhenoAge, and GrimAge2

EAD are in years; effect estimates for DunedinPoAm are in standard deviations; and effect estimates for

- 777 DNAmTL EAD are in kilobases. EAD = epigenetic age deviation; MMA = methylmalonic acid. * p < 0.05; ** p < 0.01; *** p < 0.001.
- 779

780 Figure 4: Scatter plots and associations of homocysteine concentration with GrimAge2 epigenetic

781 age deviation (EAD). The transparency of points corresponds to their survey weights. Estimates are from 782 weighted generalized linear regression models and shown for average age, BMI, alcohol intake, and

783 poverty to income ratio, and for the reference level of race and ethnicity, education level, and occupation.

- Interaction p-value for never smokers vs. former smokers = 0.27. * p < 0.05; ** p < 0.01.
- 785





Adjusted for smoking status and alcohol intake



-0.06

-0.03

0.00

0.03

0.00 (-0.02, 0.03)

0.06











